Drug Information

Drug General Information
Drug ID
D0W7JZ
Former ID
DNCL002107
Drug Name
Tivozanib
Synonyms
ASP4130/AV-951
Drug Type
Small molecular drug
Indication Renal cancer [ICD9: 140-229, 189; ICD10:C64] Phase 3 [522960], [541307]
Company
Astellas Pharma US; AVEO Pharmaceuticals
Formula
C22H19ClN4O5
InChI
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
InChIKey
SPMVMDHWKHCIDT-UHFFFAOYSA-N
PubChem Compound ID
9911830
PubChem Substance ID
14882223, 24192058, 45983488, 78829796, 99302829, 99437027, 99453618, 123051118, 123087413, 123110210, 124490423, 124757081, 124955473, 125163885, 125570998, 126659904, 126731226, 131480730, 135261059, 135685196, 135685197, 135685214, 135685972, 135685973, 135685994, 135685995, 136340121, 136367363, 136920274, 137262648, 139498427, 143499542, 144115647, 144187404, 152234928, 152258283, 152344393, 160647122, 162011363, 162037498, 162201687, 163685747, 170484711, 170496628, 170502198, 172914257, 174560995, 175607447, 177748705, 178102679
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 1 Target Info Inhibitor [541307]
Vascular endothelial growth factor receptor 3 Target Info Modulator [550325]
Vascular endothelial growth factor receptor 2 Target Info Modulator [550325]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
Endocytosis
PI3K-Akt signaling pathway
Focal adhesion
Transcriptional misregulation in cancer
Rheumatoid arthritishsa04014:Ras signaling pathway
Focal adhesionhsa04014:Ras signaling pathway
VEGF signaling pathway
Proteoglycans in cancer
NetPath Pathway TNFalpha Signaling PathwayNetPath_14:IL2 Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathway
Pathway Interaction Database Glypican 1 network
HIF-2-alpha transcription factor network
S1P3 pathway
VEGF and VEGFR signaling network
VEGFR1 specific signals
Signaling events mediated by VEGFR1 and VEGFR2vegf_vegfr_pathway:VEGF and VEGFR signaling network
VEGFR3 signaling in lymphatic endotheliumhif2pathway:HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY network
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerizationR-HSA-195399:VEGF binds to VEGFR leading to receptor dimerizationR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferation
WikiPathways Focal Adhesion
Signaling by VEGF
AngiogenesisWP1919:Signaling by VEGFWP306:Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Angiogenesis
References
Ref 522960ClinicalTrials.gov (NCT01076010) An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301). U.S. National Institutes of Health.
Ref 541307(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6058).
Ref 541307(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6058).
Ref 550325Clinical pipeline report, company report or official report of AVEO Pharmaceuticals.